GlassScriptPhysician profile
Robert Carroll Keeley
NPI 1518903921
$11,016.96
in general payments reported to CMS, 2019-2025
32 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,916 · 2020: $1,157 · 2021: $1,964 · 2022: $1,674 · 2023: $1,442 · 2024: $1,393 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,195 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,195.29 |
| Education | $111.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,631.08 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,292.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $888.24 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $769.94 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $605.55 | 2019-2023 | Yupelri |
| Genentech USA, INC. | $473.06 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.07 | 2019-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $251.66 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $243.48 | 2019-2025 | Dupixent |
| Baxter Healthcare | $209.90 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $172.27 | 2019 | |
| Abbvie INC. | $153.95 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $151.03 | 2021-2022 | |
| Amgen INC. | $112.14 | 2021-2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $88.87 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $79.81 | 2019-2021 | |
| Inogen, INC. | $66.44 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Philips North America LLC | $64.50 | 2020-2024 | (Ak6) Vest Therapy |
| Allergan, INC. | $56.05 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $54.43 | 2023 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $49.83 | 2019 | |
| Electromed, INC. | $42.00 | 2022-2024 | Smartvest |
| Pulmonx Corporation | $37.11 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Advanced Respiratory, INC | $36.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.57 | 2019-2021 | |
| Verona Pharma, INC. | $31.48 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $25.43 | 2020 | |
| Optinose US, INC. | $20.17 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.04 | 2019 | |
| United Therapeutics Corporation | $16.82 | 2021 | |
| Shire North American Group INC | $13.52 | 2019 | |
| Horizon Therapeutics Plc | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Keeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.